NCT04575727View on ClinicalTrials.gov

Exploratory Evaluation of [11C]MPC6827

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

January 8, 2021

Primary Completion Date

June 21, 2024

Study Completion Date

June 21, 2024

Conditions
Neurodegenerative DiseasesAlzheimer DiseaseAmyotrophic Lateral Sclerosis
Interventions
DRUG

[11C]MPC6827

Subjects will receive a microdose ( 10 µg) of \[11C\]MPC6827 (dose of 20 mCi)

Trial Locations (1)

10032

Cuimc / Nyp, New York

All Listed Sponsors
lead

Columbia University

OTHER

NCT04575727 - Exploratory Evaluation of [11C]MPC6827 | Biotech Hunter | Biotech Hunter